Further, this work provides the evidence for the inhibitory role of C3aR signaling in these processes, and identifies intranasal administration of C3a as an attractive and clinically relevant therapeutic strategy to inhibit secondary neurodegeneration and improve neurological outcome after neonatal HI brain injury. This evidence concerns the gene C3AR1 and brain injury.